OTC · Biotechnology

Galera Therapeutics, Inc. (GRTX) Stock

$15.62 +0.32% OTC: GRTX Healthcare

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy.

Valuation

MetricValue
Price$15.62
Market Cap$5.93M
P/E Ratio0.05
P/B Ratio1.53
P/S Ratio0.00
EPS (TTM)$312.40
52-Week High$30.00
52-Week Low$0.09
Dividend Yield—

Financials & Margins

MetricValue
ROE-210.64%
ROA2128.57%
ROCE-114.15%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-73.0M$-51.0M$-47.0M$-20.0M$-6.0M
Net Profit$-81.0M$-62.0M$-59.0M$-19.0M$149.0M
EPS$-680.00$-460.00$-266.00$-70.00$302.00
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$83.0M$44.0M$26.0M$10.0M$7.0M
Total Liabilities$141.0M$153.0M$157.0M$154.0M$1.0M
Cash$20.0M$4.0M$18.0M$8.0M$6.0M
Borrowings$0$0$1.0M$151.0M$0

Latest News

Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million Business Wire · Aug 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-43.0M$-45.0M$-12.0M$-6.0M
Investing Cash Flow$5.0M$24.0M$27.0M$0$4.0M
Financing Cash Flow$59.0M$0$2.0M$0$0
Net Cash Flow$4.0M$-16.0M$14.0M$-10.0M$-2.0M
Free Cash Flow$-68.0M$-43.0M$-45.0M$-12.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA—
FCF Yield-101.23%
Quick Ratio5.31
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Institutional HolderSharesReport Date
Ascentis Independent Advisors932026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
HOOKHOOKIPA Pharma Inc. $1.15 +0.00% -0.71 $14.40M 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
PTPIPetros Pharmaceuticals, Inc. $0.00 — 0.00 $131354 0.00%

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

Galera Therapeutics, Inc. is headquartered in US.

Galera Therapeutics, Inc. (GRTX) stock trades at $15.62 with a market capitalization of $5.93M. The stock is valued at a price-to-earnings (P/E) ratio of 0.05, price-to-book of 1.53, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.09 and $30.00, and currently trades 47.9% below its 52-week high.

On profitability, Galera Therapeutics, Inc. generates a return on equity (ROE) of -210.64%, return on capital employed of -114.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.galeratx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides